These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 15534031)

  • 21. Tolterodine causes measurable restoration of urethral sensation in women with urge urinary incontinence.
    Kenton K; Lowenstein L; Brubaker L
    Neurourol Urodyn; 2010 Apr; 29(4):555-7. PubMed ID: 19771598
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tolterodine immediate release improves sexual function in women with overactive bladder.
    Hajebrahimi S; Azaripour A; Sadeghi-Bazargani H
    J Sex Med; 2008 Dec; 5(12):2880-5. PubMed ID: 18785896
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Probable interaction between tolterodine and warfarin.
    Taylor JR
    Pharmacotherapy; 2006 May; 26(5):719-21. PubMed ID: 16718947
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cognitive, behavioral, and physiological changes in Alzheimer disease patients as a function of incontinence medications.
    Jewart RD; Green J; Lu CJ; Cellar J; Tune LE
    Am J Geriatr Psychiatry; 2005 Apr; 13(4):324-8. PubMed ID: 15845759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial.
    Leung DY; Kwong YY; Lam DS
    Br J Clin Pharmacol; 2005 Dec; 60(6):668; author reply 669. PubMed ID: 16305595
    [No Abstract]   [Full Text] [Related]  

  • 26. Urinary incontinence management: new questions from old assumptions.
    DuBeau CE
    J Am Geriatr Soc; 2001 Jun; 49(6):829-30. PubMed ID: 11454125
    [No Abstract]   [Full Text] [Related]  

  • 27. Mixed incontinence.
    Wein AJ
    J Urol; 2005 Jun; 173(6):2055-7. PubMed ID: 15879826
    [No Abstract]   [Full Text] [Related]  

  • 28. Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis.
    Harvey MA; Baker K; Wells GA
    Am J Obstet Gynecol; 2001 Jul; 185(1):56-61. PubMed ID: 11483904
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative adherence to oxybutynin or tolterodine among older patients.
    Gomes T; Juurlink DN; Mamdani MM
    Eur J Clin Pharmacol; 2012 Jan; 68(1):97-9. PubMed ID: 21710237
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder.
    Jacquetin B; Wyndaele J
    Eur J Obstet Gynecol Reprod Biol; 2001 Sep; 98(1):97-102. PubMed ID: 11516807
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Review. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine.
    Kobelt G; Kirchberger I; Malone-Lee J
    BJU Int; 1999 Apr; 83(6):583-90. PubMed ID: 10233562
    [No Abstract]   [Full Text] [Related]  

  • 32. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
    Abrams P; Kaplan S; De Koning Gans HJ; Millard R
    J Urol; 2006 Mar; 175(3 Pt 1):999-1004; discussion 1004. PubMed ID: 16469601
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A meta-analysis documenting the optimal tolerance profile of tolterodine].
    Rev Med Suisse; 2006 May; 2(65):1234. PubMed ID: 16767876
    [No Abstract]   [Full Text] [Related]  

  • 34. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients.
    Zinner NR; Mattiasson A; Stanton SL
    J Am Geriatr Soc; 2002 May; 50(5):799-807. PubMed ID: 12028164
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety profile of tolterodine as used in general practice in England: results of prescription-event monitoring.
    Layton D; Pearce GL; Shakir SA
    Drug Saf; 2001; 24(9):703-13. PubMed ID: 11522122
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of efficacy of oxybutynin and tolterodine for prevention of catheter related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study.
    Agarwal A; Dhiraaj S; Singhal V; Kapoor R; Tandon M
    Br J Anaesth; 2006 Mar; 96(3):377-80. PubMed ID: 16415311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder.
    Drutz HP; Appell RA; Gleason D; Klimberg I; Radomski S
    Int Urogynecol J Pelvic Floor Dysfunct; 1999; 10(5):283-9. PubMed ID: 10543335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparisons of efficacy and safety of tolterodine and oxybutynin in children with idiopathic overactive bladder].
    Deng YJ; Ma G; Guo YF; Ge Z; Lu RG; Wang LX; Zhu HB; Chen CJ
    Zhongguo Dang Dai Er Ke Za Zhi; 2011 Jan; 13(1):26-8. PubMed ID: 21251382
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benefit-risk assessment of tolterodine in the treatment of overactive bladder in adults.
    Garely AD; Burrows L
    Drug Saf; 2004; 27(13):1043-57. PubMed ID: 15471509
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of tolterodine in nonneurogenic voiding dysfunction.
    Babu R
    Indian Pediatr; 2006 Nov; 43(11):980-3. PubMed ID: 17151401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.